{"id":"https://openalex.org/W2186728337","doi":null,"title":"Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3.","display_name":"Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3.","publication_year":2007,"publication_date":"2007-03-01","ids":{"openalex":"https://openalex.org/W2186728337","mag":"2186728337","pmid":"https://pubmed.ncbi.nlm.nih.gov/17436590"},"language":"en","primary_location":{"id":"pmid:17436590","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17436590","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"In vivo (Athens, Greece)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050494779","display_name":"Olga Belochitski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124227911","display_name":"Ben-Gurion University of the Negev","ror":"https://ror.org/05tkyf982","country_code":"IL","type":"education","lineage":["https://openalex.org/I124227911"]},{"id":"https://openalex.org/I2800633300","display_name":"Soroka Medical Center","ror":"https://ror.org/003sphj24","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2800633300","https://openalex.org/I64767286"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Olga Belochitski","raw_affiliation_strings":["Department of Oncology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University Cancer Research Center, Beer-Sheva, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University Cancer Research Center, Beer-Sheva, Israel","institution_ids":["https://openalex.org/I124227911","https://openalex.org/I2800633300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043020044","display_name":"Samuel Ariad","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Samuel Ariad","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001152646","display_name":"Shraga Shany","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shraga Shany","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Vladimir Fridman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vladimir Fridman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5005635917","display_name":"Vladimir Gavrilov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vladimir Gavrilov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3471,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.60450649,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"21","issue":"2","first_page":"371","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9739999771118164},{"id":"https://openalex.org/keywords/du145-cells","display_name":"DU145 cells","score":0.9190000295639038},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/1-25-dihydroxyvitamin-d3","display_name":"1,25-dihydroxyvitamin D3","score":0.996999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6510000228881836},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.9539999961853027},{"id":"https://openalex.org/keywords/androgen-resistance","display_name":"androgen resistance","score":0.718999981880188},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8859999775886536},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.8640000224113464},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.800000011920929}],"concepts":[{"id":"https://openalex.org/C2776438761","wikidata":"https://www.wikidata.org/wiki/Q5206280","display_name":"DU145","level":5,"score":0.974632978439331},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.758793294429779},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.6450375914573669},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5704439878463745},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5504780411720276},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5248140096664429},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.469435453414917},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.433685839176178},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.42750057578086853},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.41489237546920776},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41220176219940186},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.34280699491500854},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3048052191734314},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.26671746373176575},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.08158653974533081},{"id":"https://openalex.org/C2779723316","wikidata":"https://www.wikidata.org/wiki/Q6459234","display_name":"LNCaP","level":4,"score":0.05906364321708679},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.05638644099235535}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D002117","descriptor_name":"Calcitriol","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:17436590","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17436590","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"In vivo (Athens, Greece)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1525448487","https://openalex.org/W1591748710","https://openalex.org/W1964071325","https://openalex.org/W1972422162","https://openalex.org/W1984912186","https://openalex.org/W1986527803","https://openalex.org/W1998843836","https://openalex.org/W2008841550","https://openalex.org/W2019234769","https://openalex.org/W2023660230","https://openalex.org/W2037593596","https://openalex.org/W2041868422","https://openalex.org/W2043911313","https://openalex.org/W2045694562","https://openalex.org/W2051570504","https://openalex.org/W2059167706","https://openalex.org/W2069637592","https://openalex.org/W2081476109","https://openalex.org/W2087032518","https://openalex.org/W2093473720","https://openalex.org/W2111693820","https://openalex.org/W2116762360","https://openalex.org/W2123284520","https://openalex.org/W2134989772","https://openalex.org/W2137600224","https://openalex.org/W2160425081","https://openalex.org/W2164729064","https://openalex.org/W2461165402"],"related_works":["https://openalex.org/W4253150101","https://openalex.org/W2257015288","https://openalex.org/W1982189347","https://openalex.org/W3185822430","https://openalex.org/W2047002642","https://openalex.org/W2018640158","https://openalex.org/W3007455850","https://openalex.org/W2098716725","https://openalex.org/W1967017933","https://openalex.org/W2040246237"],"abstract_inverted_index":{"BACKGROUND:":[0],"Targeting":[1],"of":[2,23,34,62,66,94,109,150],"the":[3,25,35,67,100,124,133],"epidermal":[4],"growth":[5,83,159],"factor":[6],"receptor":[7],"(EGFR)":[8],"pathway":[9],"is":[10],"a":[11,32,60,90,107,163],"promising":[12],"treatment":[13,105],"strategy":[14],"for":[15,165],"aggressive":[16],"androgen-refractory":[17],"prostate":[18],"cancer":[19],"(PCa).":[20],"The":[21,64],"effect":[22,65],"treating":[24],"androgen-resistant":[26],"PCa":[27,157],"cell":[28,70,82,115,158],"line":[29],"DU145":[30,48,81,114],"with":[31,52,106],"combination":[33,61,108,149],"anti-EGFR":[36],"drug":[37],"cetuximab":[38,110,151],"and":[39,73,88,111,126,142,152,160],"1,25-dihydroxyvitamin":[40],"D3":[41],"(1,25(OH)2D3)":[42],"was":[43,75],"evaluated.":[44,76],"MATERIALS":[45],"AND":[46],"METHODS:":[47],"cells":[49],"were":[50],"treated":[51],"5":[53],"nM":[54,57],"cetuximab,":[55],"100":[56],"1,25(OH)2D3":[58,112,153],"or":[59],"both.":[63],"treatments":[68,79],"on":[69],"growth,":[71],"cell-cycle":[72,101,121],"apoptosis":[74,128],"RESULTS:":[77],"Single-drug":[78],"decreased":[80],"by":[84,117,129],"up":[85],"to":[86,132],"25%":[87],"caused":[89,119],"1.5-to":[91],"1.7-fold":[92],"increase":[93],"apoptosis,":[95],"but":[96],"did":[97],"not":[98],"affect":[99],"distribution.":[102],"However,":[103],"dual":[104],"inhibited":[113],"proliferation":[116],"40%,":[118],"considerable":[120],"arrest":[122],"in":[123],"Go/Gl-phase,":[125],"enhanced":[127],"2.5-fold":[130],"(compared":[131],"control,":[134],"p":[135,139,143],"<":[136],"0.":[137],"0001,":[138,145],"<0.":[140,144],"006":[141],"respectively).":[146],"CONCLUSION:":[147],"A":[148],"efficiently":[154],"suppresses":[155],"hormone-resistant":[156],"could":[161],"provide":[162],"basis":[164],"its":[166],"clinical":[167],"application.":[168]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}